Clinical Trial Update: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies [Phase 1]

View source ↗

Summary

Tinostamustine, a first-in-class alkylating HDAC inhibitor fusion molecule, completed its Phase 1 study in relapsed/refractory hematologic malignancies, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Hodgkin Lymphoma
• Multiple Myeloma

Drugs mentioned

• Tinostamustine (tinostamustine)

Snippet

Sponsor: Mundipharma Research Limited | Conditions: Hematological Malignancies, Multiple Myeloma | Phase 1 | Status: COMPLETED